

Catalog # 10-4511 Ruxolitinib

CAS# 941678-49-5 INCB 018424 βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile Lot # FBS2072



Potent and selective JAK1&2 inhibitor, $IC_{50}s=2.7$, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.¹ Blocks IL-6 signaling ($IC_{50}=281$ nM) and proliferation of JAK2^{V617F+} Ba/F3 cells ($IC_{50}=127$ nM).² Inhibits the proinflammatory secretome of senescent cells.³ The JAK1 S646P mutant is highly sensitive to ruxolitinib.⁴ Clinically useful cancer chemotherapeutic.

- 1) Verstovsek *et al.* (2009), *Therapeutic potential of JAK2 inhibitors*; Hematology Am. Soc. Hematol. Educ. Program, **2009(1)** 636
- 2) Quintas-Cardama *et al.* (2010), *Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms*; Blood, **115** 3109
- 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med., 23 1072
- *4)* Li *et al.* (2017) *Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia*; Oncotarget, **8** 34687

PHYSICAL DATA

Molecular Weight:	306.37
Molecular Formula:	C ₁₇ H ₁₈ N ₆
Purity:	99% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 28 mg/ml) or Ethanol (up to 15 mg/ml with warming)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in
	DMSO or ethanol may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.